| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $33.8M | -48.7% |
| SG&A Expense | $18.5M | -20.9% |
| Operating Income | -$59.1M | +34.8% |
| Pre-tax Income | -$56.0M | +33.1% |
| Income Tax | $0 | — |
| Net Income | -$56.0M | +33.1% |
| EPS (Basic) | -$7.66 | +33.3% |
| EPS (Diluted) | -$7.66 | +33.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $71.9M | +72.2% |
| Short-term Investments | $0 | -100.0% |
| Current Assets | $75.7M | -44.9% |
| Total Assets | $76.6M | -47.0% |
| Current Liabilities | $6.6M | -67.7% |
| Long-term Debt | $0 | -100.0% |
| Total Liabilities | $6.6M | -76.3% |
| Stockholders' Equity |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$51.8M | +30.2% |
| Capital Expenditures | $8K | -72.4% |
| Investing Cash Flow | $92.5M | +15.0% |
| Financing Cash Flow | -$10.6M | — |
| Free Cash Flow | -$51.8M | +30.2% |
| $70.1M |
| -40.1% |